Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.62 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | HMGCR | P04035 | 6/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129907 | 0.83 | RXRA (0.68) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL526488 | 0.83 | RXRA (0.68) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL526489 | 0.83 | RXRA (0.68) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL18696397 | 0.81 | RXRA (0.65) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL1843198 | 0.81 | RXRA (0.75) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL1844436 | 0.81 | RXRA (0.75) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL29466456 | 0.81 | RXRA (0.75) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL29419163 | 0.80 | RXRA (0.67) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL8846271 | 0.80 | RXRA (0.64) | RXRAPRKAA2NR1I2NR4A2PDE4D | |
| SCHEMBL244423 | 0.80 | RXRA (0.67) | RXRAPRKAA2NR1I2NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | RXRA 1879/4885PRKAA2 317/4885NR1I2 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.